ATE293169T1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents
Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machenInfo
- Publication number
- ATE293169T1 ATE293169T1 AT02729440T AT02729440T ATE293169T1 AT E293169 T1 ATE293169 T1 AT E293169T1 AT 02729440 T AT02729440 T AT 02729440T AT 02729440 T AT02729440 T AT 02729440T AT E293169 T1 ATE293169 T1 AT E293169T1
- Authority
- AT
- Austria
- Prior art keywords
- latency
- pharmaceutically active
- fusion protein
- nucleic acid
- construct
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 101800001155 Latency-associated peptide Proteins 0.000 abstract 2
- 102400000401 Latency-associated peptide Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006337 proteolytic cleavage Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE293169T1 true ATE293169T1 (de) | 2005-04-15 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02729440T ATE293169T1 (de) | 2001-01-09 | 2002-01-09 | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (de) |
| EP (1) | EP1349944B1 (de) |
| JP (1) | JP4201253B2 (de) |
| AT (1) | ATE293169T1 (de) |
| AU (1) | AU2002219345B2 (de) |
| DE (1) | DE60203692T2 (de) |
| DK (1) | DK1349944T3 (de) |
| ES (1) | ES2240740T3 (de) |
| GB (1) | GB0100551D0 (de) |
| WO (1) | WO2002055098A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| CN101044154A (zh) * | 2002-02-14 | 2007-09-26 | 威廉·J·鲁特 | 治疗宿主中切割的嵌合分子 |
| WO2007044321A2 (en) * | 2005-10-04 | 2007-04-19 | Greenville Hospital System | Latent procytotoxins and uses thereof |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| EP2091568A2 (de) * | 2006-10-31 | 2009-08-26 | East Carolina University | Fusionsproteine mit einem entzündungshemmenden zytokin und einem antigen zur behandlung von immunerkrankungen |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) * | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| EP3348275A3 (de) | 2009-03-31 | 2018-10-24 | East Carolina University | Cytokine und neuroantigene zur behandlung von immunerkrankungen |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| WO2011123683A2 (en) * | 2010-04-02 | 2011-10-06 | University Of Rochester | Protease activated cytokines |
| EP2878308B1 (de) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| AU2019271147A1 (en) | 2018-05-14 | 2020-12-17 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| WO2020069398A1 (en) | 2018-09-27 | 2020-04-02 | Akrevia Therapeutics Inc. | Masked cytokine polypeptides |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| WO2021097376A1 (en) * | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| EP4133085A1 (de) | 2020-04-10 | 2023-02-15 | CytomX Therapeutics, Inc. | Aktivierbare cytokinkonstrukte und verwandte zusammensetzungen und verfahren |
| EP4251187A4 (de) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | Tumorspezifische spaltbare linker |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) * | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| JPH05503003A (ja) | 1989-11-22 | 1993-05-27 | ジェネンテク，インコーポレイテッド | 潜在性関与ペプチドおよびその使用 |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| EP2272959A1 (de) | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 Zusammenstellungen |
| EP0704532B1 (de) | 1994-06-10 | 2002-09-11 | United States Surgical Corporation | Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| EP0854929A1 (de) * | 1995-09-27 | 1998-07-29 | Medical Research Council | Rekombinante viren, die ein bei einer protease spaltbares protein enthalten |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| CA2288943C (en) * | 1997-04-30 | 2011-02-01 | De Novo Enzyme Corporation | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| EP1117805A2 (de) | 1998-10-07 | 2001-07-25 | STRYKER CORPORATION (a Michigan corporation) | Modifizierte proteine der tgf-beta superfamilie |
| JP2004508838A (ja) * | 2000-09-11 | 2004-03-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 組合せ蛍光エネルギー移動タグ及びそれらの使用 |
-
2001
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
-
2002
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 EP EP02729440A patent/EP1349944B1/de not_active Expired - Lifetime
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1349944A2 (de) | 2003-10-08 |
| ES2240740T3 (es) | 2005-10-16 |
| GB0100551D0 (en) | 2001-02-21 |
| US20020151478A1 (en) | 2002-10-17 |
| WO2002055098A2 (en) | 2002-07-18 |
| WO2002055098A3 (en) | 2002-11-21 |
| JP4201253B2 (ja) | 2008-12-24 |
| DK1349944T3 (da) | 2005-07-25 |
| US6942853B2 (en) | 2005-09-13 |
| DE60203692T2 (de) | 2006-03-02 |
| EP1349944B1 (de) | 2005-04-13 |
| AU2002219345B2 (en) | 2006-03-16 |
| DE60203692D1 (de) | 2005-05-19 |
| JP2004520031A (ja) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| ATE500323T1 (de) | Subtilisin-variante | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
| YU8997A (sh) | Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži | |
| WO2002014358A3 (en) | Novel secreted proteins and their uses | |
| BR9814276A (pt) | Antìgenos de superfìcie | |
| WO2002008277A3 (en) | Nucleic acids, vectors, host cells, polypeptides, and uses thereof | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| AU2003222717A8 (en) | Streptavidin-binding peptide | |
| DE69941433D1 (de) | Von protease typ ii spaltbares peptid | |
| WO2002022662A3 (en) | Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor | |
| DK1904529T3 (da) | Anvendelse af Stefin A som et scaffoldprotein | |
| ATE503834T1 (de) | Bibliotheken rekombinanter chimärischer proteine | |
| WO2004053117A3 (en) | Serine protease | |
| WO2002016578A3 (en) | Secreted proteins and methods of using same | |
| WO2002012475A3 (en) | C1q-related factor, homologous polypeptides and therapeutic uses thereof | |
| ATE278011T1 (de) | Human dnase ii | |
| DE60015559D1 (de) | Sentrin-spezifische menschliche protease senp1 | |
| FR2813606B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
| ATE427355T1 (de) | Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna | |
| TH62241A (th) | ไบคูนินของคน | |
| WO2002000709A3 (en) | Cerebellin homologous polypeptides and therapeutic uses thereof | |
| WO2003031463A3 (en) | 14081, a human trypsin-like serine protease family member and uses therefor | |
| WO2002068464A3 (de) | Fusionsprotein zum blocken des hiv nef-proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |